Brello Health Review: Tirzepatide, Real Pricing, and Is It Legit?

What does Brello Health actually sell?

Brello Health, legally Brello, LLC (doing business as Brello Health), is a Texas-based telehealth company selling compounded GLP-1 medication alongside a small menu of wellness add-ons. The core products are compounded tirzepatide, formulated with B6 to help with nausea, and compounded semaglutide, both prescribed after an online provider review and dispensed through a named, licensed pharmacy partner. Beyond the GLP-1s, Brello also sells compounded NAD+, sermorelin, glutathione, and a MICC injection (methionine, inositol, choline, cyanocobalamin) as standalone or stackable add-ons — none of these are FDA-approved finished drugs either, since compounding by definition means a pharmacy is preparing them to an individual prescription rather than a manufacturer producing and testing a mass-market batch.

That matters for a simple reason: everything in Brello's current catalog is compounded. There's no FDA-approved brand-name option here — no Zepbound, no Wegovy, no Ozempic or Mounjaro path through Brello the way some competitors broker access to the manufactured drug alongside a compounded one. If you specifically want the FDA-approved version of tirzepatide or semaglutide, Brello isn't set up to get you there; it's built entirely around the compounded lane.

Brello isn't the pharmacy itself. The compounding is handled by Southend Pharmacy, operated by AP Max, Inc., a Houston-based 503A compounding pharmacy that describes itself as LegitScript certified. That relationship isn't advertised anywhere on Brello's marketing pages — it only surfaces in the fine print of Brello's own Terms & Conditions — which is worth knowing going in if pharmacy transparency matters to your decision.

The B6 in Brello's tirzepatide isn't unique to Brello — pairing GLP-1/GIP compounds with pyridoxine (vitamin B6) is a common formulation choice across compounded providers, marketed as a nausea aid during the early weeks of treatment. It's an injection, not a tablet, delivered weekly like the branded Zepbound and Mounjaro products it's chemically related to. Like every compounded GLP-1 on the market — Brello's included — no compounder has published clinical trial data specific to its own formulation; the underlying molecule's safety and efficacy data comes from the branded drug's own trials, not from Brello's version of it. That's a category-wide caveat, not something specific to Brello, but worth understanding regardless of which compounded provider you're considering.

How the Brello process actually works

The flow follows the now-standard compounded-telehealth pattern, with a few specific details worth knowing before you start.

• Complete an online intake covering weight history, medical conditions, and current medications — Brello's own review describes this as a relatively light screening compared to some competitors' more extensive medical-history process
• A licensed provider reviews your intake and, if appropriate, completes a prescription for compounded tirzepatide, compounded semaglutide, or one of the wellness add-ons
• The prescription routes to Southend Pharmacy for compounding under 503A rules
• Medication ships to your address, typically in 3-5 business days when your state has no reported shipping delays — though delays of several weeks have been reported during at least one pharmacy transition (more on that below)
• The plan bills as a 3-month cycle, not a calendar month — $499 upfront for tirzepatide or $399 for semaglutide, auto-renewing every 11 weeks unless you cancel
• If your provider review isn't approved, you get a full refund. If you're approved and want to cancel anyway, you can get a refund minus a $50 professional-services fee — but only within 24 hours of the review being completed

Is Brello Health legitimate?

In the sense that matters most, yes: Brello runs an actual medical intake, routes every order through a licensed provider before anything is prescribed, and dispenses through a named, state-licensed 503A pharmacy rather than an anonymous supplement warehouse. As of this review, no FDA warning letter has been issued against Brello Health itself — notable given that more than 30 compounded-GLP-1 telehealth brands, including several direct competitors, received warning letters over marketing language in early 2026.

The BBB rating, and what it actually reflects

The number worth sitting with is Brello's Better Business Bureau rating: an F, not accredited, with 50 complaints closed in the last three years. That's a genuinely poor complaint-handling record for a company this size, and it's not something to wave away with 'every telehealth brand gets complaints.' Independent reviewers link at least some of that pattern to a pharmacy-transition disruption — a period where shipping reportedly slowed to four to eight weeks for some customers while billing continued on schedule, alongside complaints about slow or unanswered customer service. That specific disruption window isn't independently confirmed against Brello's own BBB complaint text in this review, but the broader pattern — shipping delays and customer-service friction — recurs across multiple independent sources, not just one.

None of that points to Brello being an unregulated or fraudulent operation — the medical process behind it is real. It does mean that if something goes sideways with your shipment or a billing question, the BBB's own record suggests you may need to be persistent about getting it resolved.

Where Brello sits in the compounded-GLP-1 regulatory picture

Compounded semaglutide and tirzepatide, Brello's included, sit on the 503A pathway — pharmacy-compounded to an individual prescription rather than manufactured as a finished, FDA-reviewed drug. The broader regulatory landscape for compounded GLP-1s remains unsettled: the FDA has moved to tighten which compounders can prepare these molecules and under what circumstances, and that picture can shift with little warning industry-wide. None of that is specific to Brello, but it's the backdrop every compounded provider in this category — Brello included — currently operates against, and it's worth knowing that the ground can move under any of them, not just the ones with a rockier reputation already.

What does Brello really cost — not just the ad price?

Brello bills in 3-month cycles rather than a monthly subscription, which is easy to misread as more expensive than it is. Compounded tirzepatide runs $499 for a 3-month cycle, working out to roughly $166 a month. Compounded semaglutide runs $399 for the same cycle length, about $133 a month. Both renew automatically every 11 weeks — not exactly three calendar months, which is worth noting when you're budgeting an exact annual figure.

The genuinely useful detail here: that price is flat. By every source checked, Brello doesn't raise your monthly-equivalent rate as your provider titrates your dose upward, the way some compounded-GLP-1 competitors do. If you're planning to reach a full maintenance dose over several months — which is most people on tirzepatide — that flat structure means your December bill looks the same as your February one. Compare that against a provider whose price climbs from an intro rate toward $450-500 a month at maintenance, and Brello's flat rate becomes the more predictable budget line, not just the cheaper-looking ad.

One caveat worth flagging directly: at least one third-party source described a separate promotional structure — a $99 first month, then $249 a month — that doesn't match the $499-per-3-months figure confirmed live on Brello's own product pages. It's possible that's an older or regionally different offer. Get your specific price in writing during intake rather than assuming either figure applies to you.

What do real Brello customers say?

On Trustpilot, Brello holds a 4.2 out of 5 rating across 4,457 reviews, with 68% five-star and a recurring theme of satisfied customers citing price, ease of use, and genuine weight-loss results. The remaining 15% one-star reviews cluster around a consistent set of complaints: shipping delays (especially reported on first orders), inconsistent customer service response times, and billing continuing after a cancellation attempt. That's a mixed-but-mostly-positive picture, not a red flag on its own — plenty of telehealth brands in this category show a similar split between a strong majority of satisfied users and a vocal minority with real operational complaints.

The BBB complaint pattern echoes the Trustpilot minority more than the majority: delayed shipments, difficulty reaching support, and billing disputes tied to cancellation timing. Reddit discussion specific to Brello is notably thin compared to larger competitors like Mochi Health or Medvi — worth knowing if you were hoping to cross-reference a large body of peer experience before enrolling; there simply isn't as much public discussion to draw from yet.

Brello vs. other compounded GLP-1 telehealth options

Henry Meds — also flat-priced, higher ceiling

Henry Meds shares Brello's flat-pricing philosophy but at a different price point: compounded tirzepatide runs $349/mo oral or $449/mo injectable, all-in, with no separate membership fee — both meaningfully above Brello's $166/mo equivalent. If your priority is the absolute lowest flat monthly number, Brello currently undercuts Henry Meds; if you want a longer track record and a more visible pharmacy relationship, Henry Meds is worth pricing against directly.

Mochi Health — two-part billing, ABOM-credentialed providers

Mochi Health splits its price into a membership fee plus a dose-based medication charge, landing around $178-$278 a month all-in for tirzepatide depending on dose — higher than Brello's flat rate at the low end, comparable to it near the top. Mochi leans harder on obesity-medicine credentialing (ABOM-certified physicians) than Brello currently advertises, which may matter more to you than the price gap itself.

Against both, Brello's pitch is straightforward: the lowest flat monthly-equivalent price among the three, in exchange for a thinner public track record and a BBB complaint history worth reading before you commit. If you're weight-loss-outcome-focused and price-sensitive first, Brello is worth serious consideration. If a longer reputation history or specific provider credentials matter more, Henry Meds or Mochi Health may be the safer starting point. For dose-specific pricing research on tirzepatide more broadly, the cheapest tirzepatide providers roundup and the compounded tirzepatide legitimacy breakdown are both useful next reads.

Brello vs. Medvi — flat price vs. dose-escalating price

It's also worth naming the structural difference against Medvi, another compounded-GLP-1 telehealth brand built around a discounted intro rate. Medvi's tirzepatide starts cheap — around $279 the first month — then climbs with your dose toward roughly $449-$499 a month at maintenance, and it carries an FDA warning letter over how it marketed that comparison to the branded drugs. Brello's model inverts that: no cheap teaser rate, but the flat $166/mo equivalent holds steady whether you're at your starting dose or your maintenance dose, and no FDA warning letter has been issued against Brello itself as of this review. Which is the better deal depends entirely on how far you expect to titrate — Medvi can be cheaper in month one, Brello is very likely cheaper by month four or five for most patients working toward a full maintenance dose.

Who Brello is right for — and who should look elsewhere

• Cost-driven and dose-flexible — the flat $166/mo tirzepatide and $133/mo semaglutide rates don't rise as you titrate, which rewards patients expecting to reach a full maintenance dose
• Comfortable with a compounded product — Brello's entire catalog is 503A compounded; there's no brand-name path through this specific provider
• Wants bundled wellness extras — virtual fitness and nutrition classes, an app, and a community come included at no added cost, which some competitors charge separately for or don't offer at all
• Willing to read the cancellation terms closely — the 24-hour post-approval refund window is short, and understanding it upfront avoids a bad surprise
• Better served elsewhere: patients who want a company with a cleaner BBB record and a longer public reputation history (Henry Meds), specifically ABOM-certified obesity-medicine providers (Mochi Health), or a path to FDA-approved brand-name Zepbound or Wegovy rather than a compounded product

How to enroll — and what to check first

The intake itself moves quickly. The diligence worth doing happens before your card is charged, not after.

• Confirm your exact plan price and renewal date (every 11 weeks, not a calendar quarter) in writing before your first charge
• Verify your state is currently covered directly on Brello's site — coverage has reportedly shifted during past pharmacy transitions
• Ask which pharmacy is filling your prescription if it isn't disclosed upfront — it's Southend Pharmacy as of this review, and confirming that directly protects you if that relationship changes
• If cancellation is a live concern, note the 24-hour window after provider approval — after that, no partial refund applies to that cycle
• Read the BBB's current complaint list before enrolling if a smooth billing and shipping experience matters as much to you as the price